171 related articles for article (PubMed ID: 25860145)
1. Serum levels of the cancer-testis antigen POTEE and its clinical significance in non-small-cell lung cancer.
Wang Q; Li X; Ren S; Cheng N; Zhao M; Zhang Y; Li J; Cai W; Zhao C; Cao W; Zhou C
PLoS One; 2015; 10(4):e0122792. PubMed ID: 25860145
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of serum thioredoxin and DJ-1 in non-small cell lung carcinoma patients.
Fan J; Yu H; Lv Y; Yin L
Tumour Biol; 2016 Feb; 37(2):1949-58. PubMed ID: 26334622
[TBL] [Abstract][Full Text] [Related]
3. Serum level of DKK-1 and its prognostic potential in non-small cell lung cancer.
Dong LL; Qu LY; Chu LY; Zhang XH; Liu YH
Diagn Pathol; 2014 Mar; 9():52. PubMed ID: 24612589
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic value of serum periostin in patients with non-small cell lung cancer.
Xu CH; Wang W; Lin Y; Qian LH; Zhang XW; Wang QB; Yu LK
Oncotarget; 2017 Mar; 8(12):18746-18753. PubMed ID: 27816968
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of serum sMICA levels in non-small cell lung cancer.
Wang LP; Niu H; Xia YF; Han YL; Niu P; Wang HY; Zhou QL
Eur Rev Med Pharmacol Sci; 2015 Jun; 19(12):2226-30. PubMed ID: 26166647
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic and prognostic value of serum Cripto-1 in patients with non-small cell lung cancer.
Xu CH; Chi CZ; Zhang Q; Wang YC; Wang W; Yuan Q; Zhan P; Zhang XW; Lin Y
Clin Respir J; 2018 Oct; 12(10):2469-2474. PubMed ID: 29570945
[TBL] [Abstract][Full Text] [Related]
7. POTEE mutation as a potential predictive biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
Li Y; Yang Q; Liu Y; Yi H; Ju Y; Qi G
Invest New Drugs; 2023 Aug; 41(4):556-563. PubMed ID: 37318657
[TBL] [Abstract][Full Text] [Related]
8. Serum macrophage inhibitory cytokine-1 as a clinical marker for non-small cell lung cancer.
Xu C; Li L; Wang W; Zhang Q; Zhang X; Yang R
J Cell Mol Med; 2021 Mar; 25(6):3169-3172. PubMed ID: 33605059
[TBL] [Abstract][Full Text] [Related]
9. Serum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosis.
Xu CH; Wang Y; Qian LH; Yu LK; Zhang XW; Wang QB
Clin Respir J; 2017 Nov; 11(6):765-771. PubMed ID: 26605871
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and Prognostic Value of Serum Angiopoietin-Like Protein 2 in Patients with Non-Small Cell Lung Cancer.
Chen Y; Jiang H; Zhu L; Wang P; Liu S; Xiao X; Yu H; Dong W
Clin Lab; 2017 Jan; 63(1):59-65. PubMed ID: 28164488
[TBL] [Abstract][Full Text] [Related]
11. The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.
Jiang AG; Chen HL; Lu HY
BMC Cancer; 2015 May; 15():386. PubMed ID: 25956656
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic Valuation of Serum miR-184 and miR-191 in Patients With Non-Small-Cell Lung Cancer.
Ding H; Wen W; Ding Q; Zhao X
Cancer Control; 2020; 27(1):1073274820964783. PubMed ID: 33104396
[TBL] [Abstract][Full Text] [Related]
13. Serum APE1 as a predictive marker for platinum-based chemotherapy of non-small cell lung cancer patients.
Zhang S; He L; Dai N; Guan W; Shan J; Yang X; Zhong Z; Qing Y; Jin F; Chen C; Yang Y; Wang H; Baugh L; Tell G; Wilson DM; Li M; Wang D
Oncotarget; 2016 Nov; 7(47):77482-77494. PubMed ID: 27813497
[TBL] [Abstract][Full Text] [Related]
14. High serum haptoglobin level is associated with tumor progression and predicts poor prognosis in non-small cell lung cancer.
Lu J; Wang Y; Yan M; Feng P; Yuan L; Cai Y; Xia X; Liu M; Luo J; Li L
Oncotarget; 2016 Jul; 7(27):41758-41766. PubMed ID: 27248178
[TBL] [Abstract][Full Text] [Related]
15. Investigation of serum miR-411 as a diagnosis and prognosis biomarker for non-small cell lung cancer.
Wang SY; Li Y; Jiang YS; Li RZ
Eur Rev Med Pharmacol Sci; 2017 Sep; 21(18):4092-4097. PubMed ID: 29028091
[TBL] [Abstract][Full Text] [Related]
16. Serum Human Epididymis Secretory Protein 4 (HE4) is a Potential Prognostic Biomarker in Non-Small Cell Lung Cancer.
Mo D; He F
Clin Lab; 2018 Sep; 64(9):1421-1428. PubMed ID: 30274019
[TBL] [Abstract][Full Text] [Related]
17. Serum angiopoietin-2 as a clinical marker for lung cancer.
Park JH; Park KJ; Kim YS; Sheen SS; Lee KS; Lee HN; Oh YJ; Hwang SC
Chest; 2007 Jul; 132(1):200-6. PubMed ID: 17505039
[TBL] [Abstract][Full Text] [Related]
18. Clinical Implications of Hepatocyte Growth Factor, Interleukin-20, and Interleukin-22 in Serum and Bronchoalveolar Fluid of Patients with Non-Small Cell Lung Cancer.
Naumnik W; Naumnik B; Niklińska W; Ossolińska M; Chyczewska E
Adv Exp Med Biol; 2016; 952():41-49. PubMed ID: 27573644
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic and prognostic significance of squamous cell carcinoma antigen in non-small cell lung cancer.
Vassilakopoulos T; Troupis T; Sotiropoulou C; Zacharatos P; Katsaounou P; Parthenis D; Noussia O; Troupis G; Papiris S; Kittas C; Roussos C; Zakynthinos S; Gorgoulis V
Lung Cancer; 2001 May; 32(2):137-44. PubMed ID: 11325484
[TBL] [Abstract][Full Text] [Related]
20. Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study.
Lang D; Horner A; Brehm E; Akbari K; Hergan B; Langer K; Asel C; Scala M; Kaiser B; Lamprecht B
Lung Cancer; 2019 Aug; 134():59-65. PubMed ID: 31319996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
